• Investing in prevention for men’s health: Increasing NHS Health Check attendance could save the NHS billions

    HealthLumen was recently commissioned by Movember, one of the leading charities changing the face of men’s health, to quantify the economic impact of men’s poor health for their ‘Real Face of Men’s Health’ 2024 UK Report.  The study found that in 2023 the five diseases that cause the largest number of years of life lost […]

  • NEWS: New genetic database analysis study reveals FNAIT risk across racially and ethnically diverse populations

    HealthLumen has recently conducted a genetic database analysis study in partnership with Rallybio, a clinical-stage biotechnology company, focused on understanding the proportions of women at higher risk for Foetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) across a broad population of diverse ancestries. The results demonstrated that the proportion of women at higher risk for FNAIT was […]

  • Supporting rare disease patient advocacy with epidemiological insights

    Awareness of the vast impact of rare diseases, which affect approximately 300 million people globally (1), has significantly increased over the years, leading to increased funding and investment in rare disease research and therapy development.   Although more than half of the novel drug approvals by the FDA’s Center for Drug Evaluation and Research last […]

  • CKD epidemic: Global prevalence and economic burden set to surge by 2027 unless action is taken, Inside CKD studies reveal

    In partnership with AstraZeneca, HealthLumen has recently published two publications that project the clinical (1) and economic (2) burden of Chronic Kidney Disease (CKD) and Kidney Replacement Therapy (KRT) into the future, as part of the “Inside CKD” programme, which contributes to the major strategic initiative at AstraZeneca dedicated to driving better patient outcomes. From […]

  • The role of precision epidemiology in R&D decision-making: Spotlight on rare genetic diseases

    Rare genetic diseases are challenging to treat due to their complexity, the unique nature of each condition, and the – by definition – small numbers of patients affected by each one.  Encouragingly for the rare disease community, the field is moving rapidly with a wide variety of innovative therapies being developed, including gene therapy involving […]

  • Securing Europe’s competitiveness in R&D for people living with rare diseases: Key takeaways from Rare Diseases Forum 2024

    Background Set against the backdrop of the Belgian Presidency of the Council of the EU, Rare Diseases Forum came to Brussels this year on April 16th, bringing together a wide range of stakeholders to discuss a European rare disease Action Plan that aims to help Europe secure competitiveness in R&D for rare disease therapies.  Although […]

  • World Kidney Day 2024: Kidney health for all

    It is estimated that a staggering 1 in 10 people worldwide are living with kidney disease (1). Despite its high global prevalence and mortality, CKD has surprisingly often been overlooked on health agendas across the globe up until now. In particular, low and middle-income countries are disproportionately affected by CKD and kidney failure, with a […]

  • How rare is rare? Quantifying the hidden population living with rare genetic diseases using genetic databases

    Rare Disease Day is fast approaching, with a programme of activity being lined up, through international initiatives and country-specific programmes, in the UK for example to highlight challenges, raise awareness and generate change for the 300 million people worldwide living with one or more of the roughly 8,000 known rare diseases, as well as their […]

  • Join us at upcoming conferences to discuss the latest findings in the epidemiology of rare diseases.

    It’s a well-established truism that rare diseases, whilst rare at the individual disease level, are collectively quite common, with some 300 million people worldwide living with a rare disease. However, are rare diseases actually as rare at the individual disease level as current estimates suggest  – what could be the extent of the “hidden population”? […]

  • NEWS: Policy interventions could reduce chronic liver disease and liver cancer in Europe by up to 7% by 2030 

    Europe has the largest burden of diagnosed liver disease globally with almost 30 million people in the European Union alone estimated to be living with a chronic liver condition. Liver cirrhosis accounts for 1.8% of all deaths reported in Europe (170,000 deaths annually) with a 100% increase in cirrhosis deaths observed across the Eastern European […]